Reproductive aspects of transgenders
Lucia Alves da Silva Lara, Paula Andrea Albuquerque Salles Navarro, Estella Thaisa Sontag dos Reis, Thays Marina Roncato Barcelos, Rosana Maria dos Reis, Maíra Cristina Ribeiro Andrade, Ana Carolina Japur de Sá Rosa e Silva, Rui Alberto Ferriani
Abstract
Objectives: The reproductive function of transgender (trans) men and women may be compromised after the implementation of gender-affirming therapy (GAT) and gender-affirming surgeries (GAS). Trans men recover their reproductive capacity months after discontinuing testosterone; however, estrogen therapy can permanently compromise the reproductive function of trans women. The aim of the present study was to discuss the reproductive aspects of transgender people, especially those who seek GAT and/or GAS to adapt their bodies to the gender with which they identify. Methods: original articles, case series, case reports, and review articles published in English and indexed in the PubMed, Google Scholar, and Embase databases were taken into consideration. Two authors selected the articles to be included, and a third author judged when there was disagreement between the former two. Results: Our search retrieved 1,628 articles. After removing duplicates, 1,426 titles were screened, 112 were considered potential, and 63 were included in this review. Conclusions: there are changes in the gonads of trans people caused by estrogen and androgen that can promote infertility in this population, perhaps temporarily or not. Thus, it is necessary to carry out reproductive counseling for this population before starting GAHT and during all medical follow-ups, especially with individuals who will undergo GAS.
Keywords
References
1. Joseph A, Cliffe C, Hillyard M, Majeed A. Gender identity and the management of the transgender patient: a guide for non-specialists. J R Soc Med. 2017;110(4):144-52. http://dx.doi.org/10.1177/0141076817696054. PMid:28382847.
2. ICD-11 for Mortality and Morbidity Statistics [Internet]. Geneva: WHO; 2023 [cited 2022 Mar 27]. Available from: https://icd.who. int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f411470068
3. Foster Skewis L, Bretherton I, Leemaqz SY, Zajac JD, Cheung AS. Short-term effects of gender-affirming hormone therapy on dysphoria and quality of life in transgender individuals: a prospective controlled study. Front Endocrinol (Lausanne). 2021;12:717766. http://dx.doi.org/10.3389/fendo.2021.717766. PMid:34394009.
4. Lerri MR, Romão APMS, Santos MAD, Giami A, Ferriani RA, Lara LAS. Características clínicas de uma amostra de pessoas transexuais. Rev Bras Ginecol Obstet. 2017;39(10):545-51. PMid:28783854.
5. Okano SHP, Franceschini SA, Lerri MR, Poli-Neto OB, Brito LGO, Lara LAS. Characteristics of a population with gender incongruence assisted at a specialized outpatient service in the city of Ribeirão Preto. Rev Bras Ginecol Obstet. 2022;44(3):258-63. http:// dx.doi.org/10.1055/s-0042-1742407. PMid:35139571.
6. Shields JP, Cohen R, Glassman JR, Whitaker K, Franks H, Bertolini I. Estimating population size and demographic characteristics of lesbian, gay, bisexual, and transgender youth in middle school. J Adolesc Health. 2013;52(2):248-50. http://dx.doi.org/10.1016/j. jadohealth.2012.06.016. PMid:23332492.
7. Collin L, Reisner SL, Tangpricha V, Goodman M. Prevalence of transgender depends on the “case” definition: a systematic review. J Sex Med. 2016;13(4):613-26. http://dx.doi.org/10.1016/j.jsxm.2016.02.001. PMid:27045261.
8. Spizzirri G, Eufrásio R, Lima MCP, Nunes HRC, Kreukels BPC, Steensma TD, et al. Proportion of people identified as transgender and non-binary gender in Brazil. Sci Rep. 2021;11(1):2240. http://dx.doi.org/10.1038/s41598-021-81411-4. PMid:33500432.
9. Flores AR, Herman JL, Gates GJ, Brown TNT. How many adults identify as transgender in the United States? (Vol. 13). Los Angeles: Williams Institute; 2016.
10. Wood H, Sasaki S, Bradley SJ, Singh D, Fantus S, Owen-Anderson A, et al. Patterns of referral to a gender identity service for children and adolescents (1976-2011): age, sex ratio, and sexual orientation. J Sex Marital Ther. 2013;39(1):1-6. http://dx.doi. org/10.1080/0092623X.2012.675022. PMid:23152965.
11. Connolly MD, Zervos MJ, Barone II CJ, Johnson CC, Joseph CLM. The mental health of transgender youth: advances in understanding. J Adolesc Health. 2016;59(5):489-95. http://dx.doi.org/10.1016/j.jadohealth.2016.06.012. PMid:27544457.
12. Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, et al. Endocrine treatment of gender-dysphoric/ gender-incongruent persons: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102(11):3869-903. http://dx.doi.org/10.1210/jc.2017-01658. PMid:28945902.
13. Moravek MB, Kinnear HM, George J, Batchelor J, Shikanov A, Padmanabhan V, et al. Impact of exogenous testosterone on reproduction in transgender men. Endocrinology. 2020;161(3):bqaa014. http://dx.doi.org/10.1210/endocr/bqaa014. PMid:32105330.
14. Costa LBF, Rosa-e-Silva ACJS, Medeiros SF, Nacul AP, Carvalho BR, Benetti-Pinto CL, et al. Recommendations for the use of testosterone in male transgender. Rev Bras Ginecol Obstet. 2018;40(5):275-80. http://dx.doi.org/10.1055/s-0038-1657788. PMid:29913543.
15. Spratt DI, Stewart II, Savage C, Craig W, Spack NP, Chandler DW, et al. Subcutaneous injection of testosterone is an effective and preferred alternative to intramuscular injection: demonstration in female-to-male transgender patients. J Clin Endocrinol Metab. 2017;102(7):2349-55. http://dx.doi.org/10.1210/jc.2017-00359. PMid:28379417.
16. Mueller A, Haeberle L, Zollver H, Claassen T, Kronawitter D, Oppelt PG, et al. Effects of intramuscular testosterone undecanoate on body composition and bone mineral density in female-to-male transsexuals. J Sex Med. 2010;7(9):3190-8. http://dx.doi. org/10.1111/j.1743-6109.2010.01912.x. PMid:20584125.
17. Maraka S, Singh Ospina N, Rodriguez-Gutierrez R, Davidge-Pitts CJ, Nippoldt TB, Prokop LJ, et al. Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2017;102(11):3914-23. http://dx.doi.org/10.1210/jc.2017-01643. PMid:28945852.
18. Defreyne J, Vantomme B, Van Caenegem E, Wierckx K, De Blok CJM, Klaver M, et al. Prospective evaluation of hematocrit in gender-affirming hormone treatment: results from European Network for the Investigation of Gender Incongruence. Andrology. 2018;6(3):446-54. http://dx.doi.org/10.1111/andr.12485. PMid:29602229.
19. Dekker MJHJ, Wierckx K, Van Caenegem E, Klaver M, Kreukels BP, Elaut E, et al. A European network for the investigation of gender incongruence: endocrine part. J Sex Med. 2016;13(6):994-9. http://dx.doi.org/10.1016/j.jsxm.2016.03.371. PMid:27162190.
20. Hannema SE, Schagen SEE, Cohen-Kettenis PT, Delemarre-van de Waal HA. Efficacy and safety of pubertal induction using 17β-Estradiol in transgirls. J Clin Endocrinol Metab. 2017;102(7):2356-63. PMid:28419243.
21. Ethics Committee of the American Society for Reproductive Medicine. Access to fertility services by transgender persons: an Ethics Committee opinion. Fertil Steril. 2015;104(5):1111-5. http://dx.doi.org/10.1016/j.fertnstert.2015.08.021. PMid:26363388.
22. Spinder T, Spijkstra JJ, van den Tweel JG, Burger CW, van Kessel H, Hompes PG, et al. The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects. J Clin Endocrinol Metab. 1989;69(1):151-7. http://dx.doi.org/10.1210/jcem-69-1-151. PMid:2471710.
23. Schönauer LM, Dellino M, Loverro M, Carriero C, Capursi T, Leoni C, et al. Hormone therapy in female-to-male transgender patients: searching for a lifelong balance. Hormones. 2021;20(1):151-9. http://dx.doi.org/10.1007/s42000-020-00238-2. PMid:33026609.
24. Vendola KA, Zhou J, Adesanya OO, Weil SJ, Bondy CA. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest. 1998;101(12):2622-9. http://dx.doi.org/10.1172/JCI2081. PMid:9637695.
25. Murray AA, Gosden RG, Allison V, Spears N. Effect of androgens on the development of mouse follicles growing in vitro. J Reprod Fertil. 1998;113(1):27-33. http://dx.doi.org/10.1530/jrf.0.1130027. PMid:9713373.
26. Ikeda K, Baba T, Noguchi H, Nagasawa K, Endo T, Kiya T, et al. Excessive androgen exposure in female-to-male transsexual persons of reproductive age induces hyperplasia of the ovarian cortex and stroma but not polycystic ovary morphology. Hum Reprod. 2013;28(2):453-61. http://dx.doi.org/10.1093/humrep/des385. PMid:23188113.
27. Feigerlová E, Pascal V, Ganne-Devonec MO, Klein M, Guerci B. Fertility desires and reproductive needs of transgender people: challenges and considerations for clinical practice. Clin Endocrinol (Oxf). 2019;91(1):10-21. http://dx.doi.org/10.1111/cen.13982. PMid:30943314.
28. De Roo C, Lierman S, Tilleman K, Peynshaert K, Braeckmans K, Caanen M, et al. Ovarian tissue cryopreservation in female-to-male transgender people: insights into ovarian histology and physiology after prolonged androgen treatment. Reprod Biomed Online. 2017;34(6):557-66. http://dx.doi.org/10.1016/j.rbmo.2017.03.008. PMid:28372892.
29. Lierman S, Tolpe A, De Croo I, De Gheselle S, Defreyne J, Baetens M, et al. Low feasibility of in vitro matured oocytes originating from cumulus complexes found during ovarian tissue preparation at the moment of gender confirmation surgery and during testosterone treatment for fertility preservation in transgender men. Fertil Steril. 2021;116(4):1068-76. http://dx.doi.org/10.1016/j. fertnstert.2021.03.009. PMid:33832736.
30. Caanen MR, Soleman RS, Kuijper EAM, Kreukels BPC, De Roo C, Tilleman K, et al. Antimüllerian hormone levels decrease in female-to-male transsexuals using testosterone as cross-sex therapy. Fertil Steril. 2015;103(5):1340-5. http://dx.doi.org/10.1016/j. fertnstert.2015.02.003. PMid:25772768.
31. Minotti F, Nagelberg A, Abdala R, Otero P. Assessment of ovarian reserve during gender affirmation hormone therapy in trans men. Medicina. 2022;82(2):238-43. PMid:35417388.
32. Loverro G, Resta L, Dellino M, Edoardo DN, Cascarano MA, Loverro M, et al. Uterine and ovarian changes during testosterone administration in young female-to-male transsexuals. Taiwan J Obstet Gynecol. 2016;55(5):686-91. http://dx.doi.org/10.1016/j. tjog.2016.03.004. PMid:27751416.
33. Carbonnel M, Karpel L, Cordier B, Pirtea P, Ayoubi JM. The uterus in transgender men. Fertil Steril. 2021;116(4):931-5. http:// dx.doi.org/10.1016/j.fertnstert.2021.07.005. PMid:34364678.
34. Light AD, Obedin-Maliver J, Sevelius JM, Kerns JL. Transgender men who experienced pregnancy after female-to-male gender transitioning. Obstet Gynecol. 2014;124(6):1120-7. http://dx.doi.org/10.1097/AOG.0000000000000540. PMid:25415163.
35. Light AD, Obedin-Maliver J, Sevelius JM, Kerns JL. Transgender men who experienced pregnancy after female-to-male gender transitioning. Obstet Gynecol. 2014;124(6):1120-7. http://dx.doi.org/10.1097/AOG.0000000000000540. PMid:25415163.
36. Okano SHP, Pellicciotta GGM, Braga GC. Contraceptive counseling for the transgender patient assigned female at birth. Rev Bras Ginecol Obstet. 2022;44(9):884-90. http://dx.doi.org/10.1055/s-0042-1751063. PMid:35793692.
37. Mancini I, Alvisi S, Gava G, Seracchioli R, Meriggiola MC. Contraception across transgender. Int J Impot Res. 2021;33(7):710-9. http://dx.doi.org/10.1038/s41443-021-00412-z. PMid:33558672.
38. Schneider F, Kliesch S, Schlatt S, Neuhaus N. Andrology of male-to-female transsexuals: influence of cross-sex hormone therapy on testicular function. Andrology. 2017;5(5):873-80. http://dx.doi.org/10.1111/andr.12405. PMid:28914501.
39. Matoso A, Khandakar B, Yuan S, Wu T, Wang LJ, Lombardo KA, et al. Spectrum of findings in orchiectomy specimens of persons undergoing gender confirmation surgery. Hum Pathol. 2018;76:91-9. http://dx.doi.org/10.1016/j.humpath.2018.03.007. PMid:29555572.
40. Adeleye AJ, Reid G, Kao CN, Mok-Lin E, Smith JF. Semen parameters among transgender women with a history of hormonal treatment. Urology. 2019;124:136-41. http://dx.doi.org/10.1016/j.urology.2018.10.005. PMid:30312673.
41. de Nie I, Meißner A, Kostelijk EH, Soufan AT, Voorn-de Warem IAC, den Heijer M, et al. Impaired semen quality in trans women: prevalence and determinants. Hum Reprod. 2020;35(7):1529-36. http://dx.doi.org/10.1093/humrep/deaa133. PMid:32613241.
42. de Nie I, Asseler J, Meißner A, Voorn-de Warem IAC, Kostelijk EH, den Heijer M, et al. A cohort study on factors impairing semen quality in transgender women. Am J Obstet Gynecol. 2022;226(3):390.e1-10. http://dx.doi.org/10.1016/j.ajog.2021.10.020. PMid:34688596.
43. Moltz L, Römmler A, Post K, Schwartz U, Hammerstein J. Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in men. Contraception. 1980;21(4):393-413. http://dx.doi.org/10.1016/S0010-7824(80)80017-5. PMid:6771095.
44. Lunglmayr G, Girsch E, Meixner EM, Viehberger G, Bieglmayer C. Effects of long term GnRH analogue treatment on hormone levels and spermatogenesis in patients with carcinoma of the prostate. Urol Res. 1988;16(4):315-9. http://dx.doi.org/10.1007/ BF00263642. PMid:2972102.
45. Linde R, Doelle GC, Alexander N, Kirchner F, Vale W, Rivier J, et al. Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive. N Engl J Med. 1981;305(12):663-7. http://dx.doi.org/10.1056/NEJM198109173051203. PMid:6267464
46. Moravek MB. Fertility preservation options for transgender and gender-nonconforming individuals. Curr Opin Obstet Gynecol. 2019;31(3):170-6. http://dx.doi.org/10.1097/GCO.0000000000000537. PMid:30870185.
47. Feigerlová E, Pascal V, Ganne-Devonec MO, Klein M, Guerci B. Fertility desires and reproductive needs of transgender people: challenges and considerations for clinical practice. Clin Endocrinol (Oxf). 2019;91(1):10-21. http://dx.doi.org/10.1111/cen.13982. PMid:30943314.
48. De Sutter P. Gender reassignment and assisted reproduction: present and future reproductive options for transsexual people. Hum Reprod. 2001;16(4):612-4. http://dx.doi.org/10.1093/humrep/16.4.612. PMid:11278204.
49. Alpern S, Yaish I, Wagner-Kolasko G, Greenman Y, Sofer Y, Paltiel Lifshitz D, et al. Why fertility preservation rates of transgender men are much lower than those of transgender women. Reprod Biomed Online. 2022;44(5):943-50. http://dx.doi.org/10.1016/j. rbmo.2022.01.003. PMid:35339365.
50. Mattelin E, Strandell A, Bryman I. Fertility preservation and fertility treatment in transgender adolescents and adults in a Swedish region, 2013-2018. Hum Reprod Open. 2022;2022(2):hoac008. http://dx.doi.org/10.1093/hropen/hoac008. PMid:35309678.
51. Brown C. Exploring trans people’s experiences of adoption and fostering in the United Kingdom: a qualitative study. Int J Transgend Health. 2021;22(1-2):89-100. http://dx.doi.org/10.1080/26895269.2020.1867396. PMid:33899048.
52. Brackett NL. Semen retrieval by penile vibratory stimulation in men with spinal cord injury. Hum Reprod Update. 1999;5(3):216- 22. http://dx.doi.org/10.1093/humupd/5.3.216. PMid:10438106.
53. Mattawanon N, Spencer JB, Schirmer III DA, Tangpricha V. Fertility preservation options in transgender people: a review. Rev Endocr Metab Disord. 2018;19(3):231-42. http://dx.doi.org/10.1007/s11154-018-9462-3. PMid:30219984.
54. Tornello SL, Bos H. Parenting intentions among transgender individuals. LGBT Health. 2017;4(2):115-20. http://dx.doi.org/10.1089/ lgbt.2016.0153. PMid:28212056.
55. Wierckx K, Van Caenegem E, Pennings G, Elaut E, Dedecker D, Van de Peer F, et al. Reproductive wish in transsexual men. Hum Reprod. 2012;27(2):483-7. http://dx.doi.org/10.1093/humrep/der406. PMid:22128292.
56. Riggs DW, Pfeffer CA, Pearce R, Hines S, White FR. Men, trans/masculine, and non-binary people negotiating conception: normative resistance and inventive pragmatism. Int J Transgend Health. 2021;22(1-2):6-17. http://dx.doi.org/10.1080/15532739.2020.180 8554. PMid:34476419.
57. Armuand G, Dhejne C, Olofsson JI, Rodriguez-Wallberg KA. Transgender men’s experiences of fertility preservation: a qualitative study. Hum Reprod. 2017;32(2):383-90. http://dx.doi.org/10.1093/humrep/dew323. PMid:27999119.
58. Ben-Haroush A, Ben-Aharon I, Lande Y, Fisch B. Use of aromatase inhibitors in IVF for fertility preservation of non-breast cancer patients: a case series. Isr Med Assoc J. 2018;20(3):145-6. PMid:29527850.
59. Sterling J, Garcia MM. Fertility preservation options for transgender individuals. Transl Androl Urol. 2020;9(Suppl 2):S215-26. http://dx.doi.org/10.21037/tau.2019.09.28. PMid:32257862.
60. Shih KW, Shen PY, Wu CC, Kang YN. Testicular versus percutaneous epididymal sperm aspiration for patients with obstructive azoospermia: a systematic review and meta-analysis. Transl Androl Urol. 2019;8(6):631-40. http://dx.doi.org/10.21037/ tau.2019.11.20. PMid:32038959.
61. Coleman E, Bockting W, Botzer M, Cohen-Kettenis P, DeCuypere G, Feldman J, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgenderism. 2012;13(4):165-232. http://dx.doi.org/10.10 80/15532739.2011.700873.
62. Moravek MB. Fertility preservation options for transgender and gender-nonconforming individuals. Curr Opin Obstet Gynecol. 2019;31(3):170-6. http://dx.doi.org/10.1097/GCO.0000000000000537. PMid:30870185.
63. Chen D, Simons L, Johnson EK, Lockart BA, Finlayson C. Fertility preservation for transgender adolescents. J Adolesc Health. 2017;61(1):120-3. http://dx.doi.org/10.1016/j.jadohealth.2017.01.022. PMid:28363716.
64. Riggs DW, Bartholomaeus C. Fertility preservation decision making amongst Australian transgender and non-binary adults. Reprod Health. 2018;15(1):181. http://dx.doi.org/10.1186/s12978-018-0627-z. PMid:30359260.
65. Safer JD, Coleman E, Feldman J, Garofalo R, Hembree W, Radix A, et al. Barriers to healthcare for transgender individuals. Curr Opin Endocrinol Diabetes Obes. 2016;23(2):168-71. http://dx.doi.org/10.1097/MED.0000000000000227. PMid:26910276.
Submitted date:
03/12/2023
Accepted date:
10/19/2023
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email